Sigfox Collaborates with Google Cloud to Accelerate its Global IoT Strategy
11.2.2021 12:10:00 EET | Business Wire | Press release
Google Cloud and Sigfox today announced that the leading global 0G network and IoT platform services provider, has partnered with Google Cloud, to scale its cloud infrastructure and extend its IoT services portfolio. This partnership will enable Sigfox to rapidly accelerate its “Massive IoT” agenda – processing billions of messages each month from objects connected to the internet using data stored in the cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005380/en/
Sigfox is the world’s largest dedicated LPWAN service provider for connecting simple, low-powered, low-cost IoT devices to the Internet. Already deployed in 72 countries, covering more than 1.3 billion people, Sigfox’s 0G network is used for a wide range of IoT use cases from tracking shipping containers and monitoring fire hydrants, to securing buildings and helping farmers monitor irrigation levels. In recent years due to an explosion in the number of internet-connected devices, Sigfox now processes billions of messages each month (an increase of 145% in 2020) from the millions of objects connected to its network–and the company needed a more scalable, long-term solution.
Google Cloud was chosen as the backbone for Sigfox’s 0G network to bring better scale, increased reliability, and best-of-breed compliance and security to Sigfox’s platform. Google Cloud will also enable faster improvements to Sigfox’s connectivity, geolocation, and other value-added services towards ultra-low-cost and ultra-low-power IoT solutions.
Sigfox’s shift to the cloud will transform many of the applications across the range of industries in which it operates including supply chain and logistics, automotive, postal services and utilities. This includes the Sigfox auto parts solution which tracks components on their journeys between assembly plants and suppliers with sensor-equipped containers. Or Sigfox’s solutions for utility companies that digitize the data collection of gas consumption meters, retrofitted Network Controlling Units and smart features. Also, shipping companies fit trolley rollers or containers with Sigfox smart trackers to give exact information on location, movement and condition. All of them will be now cloud-enabled, helping provide a scalable and seamless way to manage exponential data growth.
"We chose Google Cloud because we share the same appetite for driving digital transformation through helpful, reliable and sustainable innovation." said Franck Siegel, Deputy Chief Executive Officer, Sigfox. “With this partnership, Google Cloud technology will support us in becoming the global leader in ultra-low-cost, ultra-low-power asset visibility and tracking”.
“Google Cloud is proud to support Sigfox and provide an IoT leader with more reliability and flexibility as the company takes the next steps of its development,” said Samuel Bonamigo, VP Sales, EMEA South, Google Cloud. "Sigfox’s use of Google Cloud technology is the perfect illustration of how we’re helping innovative companies grow and thrive and better serve their customers.”
About Google Cloud
Google Cloud provides organizations with leading infrastructure, platform capabilities and industry solutions. We deliver enterprise-grade cloud solutions that leverage Google’s cutting-edge technology to help companies operate more efficiently and adapt to changing needs, giving customers a foundation for the future. Customers in more than 150 countries turn to Google Cloud as their trusted partner to solve their most critical business problems.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. It relies on a unique combination of ultra-low cost and ultra-low power technologies together with a global network to enable companies to gain visibility and track their assets worldwide for greater business results. With Sigfox, +17 million of devices send +60 million messages a day so that businesses can accelerate their digital transformation in key areas such as Asset Tracking and Supply Chain.
ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox has been founded in 2010 and is headquartered in France with offices in Madrid, Munich, Boston, Dallas, Dubai, Singapore, Sao Paulo and Tokyo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005380/en/
Contact information
Press Contact
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom